Eternygen UK Ltd. has disclosed 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives acting as sodium-coupled citrate transporter 5 (SLC13A5) inhibitors reported to be useful for the treatment of eating disorders, liver cancer, neurodegeneration, and liver and metabolic diseases.